250
Participants
Start Date
July 20, 2019
Primary Completion Date
December 10, 2019
Study Completion Date
January 10, 2020
Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Three doses of control wIPV, vaccinated within one-month interval between doses
Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Three doses of control sIPV, vaccinated within one-month interval between doses
Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Pizhou Center for Disease Control and Prevention, Pizhou
Sinovac Biotech Co., Ltd
INDUSTRY